Table 5.

Main ERP component findings in FXS patients compared with healthy controls.

Component	Latency	Amplitude
N1	No difference (St. Clair et al., 1987; Rojas et al., 2001; Castrèn et al., 2003; Van der Molen et al., 2012a,b)	Increased (St. Clair et al., 1987; Rojas et al., 2001; Castrèn et al., 2003 Van der Molen et al., 2012a,b)
		No habituation (Castrèn et al., 2003; Van der Molen et al., 2012a)
P2	No difference (St. Clair et al., 1987; Van der Molen et al., 2012a,b)	Inconsistent
		Increased (St. Clair et al., 1987; Van der Molen et al., 2012a)
		No difference (Van der Molen et al., 2012b)
MMN	No difference, Trend: prolonged, n.s. (Van der Molen et al., 2012a)	Decreased (Van der Molen et al., 2012a)
N2	Prolonged (St. Clair et al., 1987; Van der Molen et al., 2012a,b)	Inconsistent
		No difference (St. Clair et al., 1987)
		Increased (Van der Molen et al., 2012a,b)
P3	Prolonged (St. Clair et al., 1987; Van der Molen et al., 2012a,b)	Decreased (St. Clair et al., 1987; Van der Molen et al., 2012a,b)